The report by Echevarría‐Vargas and colleagues in this issue of EMBO Molecular Medicine (Echevarría‐Vargas et al, 2018) describes a potential new treatment strategy by targeting BRD4 and TCF19 downstream of NRAS, demonstrating that inhibition of both the BRD4 and MEK pathways arrests and kills both NRAS‐mutant melanoma and immunotherapy‐resistant melanoma cells in vivo (Fig 1). This evidence concerns the gene NRAS and melanoma.